Momentus Seeks Shareholder Approval for Over 100% Dilution via Deeply Discounted Warrants to Fund Operations

summarizeSummary

This preliminary proxy statement reveals Momentus Inc.'s urgent need for capital, highlighted by its explicit statement that its ability to continue as a going concern depends on maximizing capital raising opportunities, including these warrant exercises. The company is proposing to issue approximately 1.75 million new shares from the exercise of October 2025, December 2025, and January 2026 warrants, which collectively represent over 100% dilution based on current outstanding shares. Notably, the exercise prices for the October and December 2025 warrants were recently amended downwards to $5.40 per share, matching the January 2026 warrants, which is a significant discount to the current stock price of $9.73. While these exercises could bring in nearly $9.5 million in much-needed capital, the substantial dilution and the unfavorable pricing terms underscore the company's precarious financial position and its reliance on these measures to fund ongoing operations.

check_boxKey Events

• Massive Potential Dilution

  Shareholders are asked to approve the issuance of approximately 1.75 million Class A common shares from warrant exercises, representing over 100% dilution of current outstanding shares.

• Critical Capital Raise

  The company explicitly states its "going concern" is dependent on these capital raising opportunities, indicating significant financial distress.

• Deeply Discounted Warrants

  The exercise price for the October 2025, December 2025, and January 2026 warrants is set at $5.40 per share, a significant discount compared to the current stock price of $9.73.

• Amended Warrant Terms

  Exercise prices for previously issued October and December 2025 inducement warrants were lowered to $5.40 per share, reflecting a need to make them more attractive for exercise.

auto_awesomeAnalysis

This preliminary proxy statement reveals Momentus Inc.'s urgent need for capital, highlighted by its explicit statement that its ability to continue as a going concern depends on maximizing capital raising opportunities, including these warrant exercises. The company is proposing to issue approximately 1.75 million new shares from the exercise of October 2025, December 2025, and January 2026 warrants, which collectively represent over 100% dilution based on current outstanding shares. Notably, the exercise prices for the October and December 2025 warrants were recently amended downwards to $5.40 per share, matching the January 2026 warrants, which is a significant discount to the current stock price of $9.73. While these exercises could bring in nearly $9.5 million in much-needed capital, the substantial dilution and the unfavorable pricing terms underscore the company's precarious financial position and its reliance on these measures to fund ongoing operations.